150 related articles for article (PubMed ID: 22915655)
41. The diverse diversity.
Mok TS; Lam KC
J Thorac Oncol; 2011 May; 6(5):842-3. PubMed ID: 21623264
[No Abstract] [Full Text] [Related]
42. Personalized medicine for non-small-cell lung cancer.
Kucherlapati R
Oncology (Williston Park); 2010 Apr; 24(5):399-400. PubMed ID: 20480736
[No Abstract] [Full Text] [Related]
43. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.
Rosell R; Felip E; Reguart N; Moran T
Future Oncol; 2005 Jun; 1(3):319-22. PubMed ID: 16556005
[No Abstract] [Full Text] [Related]
44. Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer.
Cathcart-Rake E; Lopez-Chavez A
J Thorac Oncol; 2014 Nov; 9(11):e83-5. PubMed ID: 25436812
[No Abstract] [Full Text] [Related]
45. Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
Bolzacchini E; Tuzi A; Gobba S; Pinotti G
J Thorac Oncol; 2017 Dec; 12(12):e208-e210. PubMed ID: 29169529
[No Abstract] [Full Text] [Related]
46. Limitations of single-strand conformation polymorphism analysis as a high-throughput method for the detection of EGFR mutations in the clinical setting.
Weber F; Fukino K; Villalona-Calero M; Eng C
J Clin Oncol; 2005 Aug; 23(24):5847-8; author reply 5848-9. PubMed ID: 16110042
[No Abstract] [Full Text] [Related]
47. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.
Guan H; Du Y; Ning Y; Cao X
Future Med Chem; 2017 May; 9(7):693-704. PubMed ID: 28504890
[TBL] [Abstract][Full Text] [Related]
48. Lung cancer: a new generation of EGFR inhibition.
Killock D
Nat Rev Clin Oncol; 2015 Jul; 12(7):373. PubMed ID: 25963089
[No Abstract] [Full Text] [Related]
49. [I. Management of Brain Metastasis in Patients with Lung Cancer].
Kubota K
Gan To Kagaku Ryoho; 2017 Jun; 44(6):475-478. PubMed ID: 28698437
[No Abstract] [Full Text] [Related]
50. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.
Ma L; Wang DD; Huang Y; Wong MP; Lee VH; Yan H
Comput Biol Med; 2015 Aug; 63():293-300. PubMed ID: 25035232
[TBL] [Abstract][Full Text] [Related]
51. Deletion Mutations Keep Kinase Inhibitors in the Loop.
Freed DM; Park JH; Radhakrishnan R; Lemmon MA
Cancer Cell; 2016 Apr; 29(4):423-425. PubMed ID: 27070691
[TBL] [Abstract][Full Text] [Related]
52. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
He Y
N Engl J Med; 2015 Aug; 373(6):578. PubMed ID: 26244319
[No Abstract] [Full Text] [Related]
53. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
Sequist LV; Rolfe L; Allen AR
N Engl J Med; 2015 Aug; 373(6):578-9. PubMed ID: 26244318
[No Abstract] [Full Text] [Related]
54. Resistance: Following different paths.
Seton-Rogers S
Nat Rev Cancer; 2016 Mar; 16(3):128. PubMed ID: 26911183
[No Abstract] [Full Text] [Related]
55. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Lynch TJ; Adjei AA; Bunn PA; Eisen TG; Engelman J; Goss GD; Haber DA; Heymach JV; Jänne PA; Johnson BE; Johnson DH; Lilenbaum RC; Meyerson M; Sandler AB; Sequist LV; Settleman J; Wong KK; Hart CS
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4365s-4371s. PubMed ID: 16857812
[No Abstract] [Full Text] [Related]
56. Personalized medicine: Lung Cancer leads the way.
Parikh P; Puri T
Indian J Cancer; 2013; 50(2):77-9. PubMed ID: 23979195
[No Abstract] [Full Text] [Related]
57. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
Mohapatra PR; Punatar S; Prabhash K
Eur Respir J; 2012 Jun; 39(6):1550-1; author reply 1551. PubMed ID: 22654017
[No Abstract] [Full Text] [Related]
58. Target Therapy in Lung Cancer.
Cafarotti S; Lococo F; Froesh P; Zappa F; Andrè D
Adv Exp Med Biol; 2016; 893():127-136. PubMed ID: 26667341
[TBL] [Abstract][Full Text] [Related]
59. The Cobas® EGFR Mutation Test v2 assay.
Brown P
Future Oncol; 2016 Feb; 12(4):451-2. PubMed ID: 26838018
[TBL] [Abstract][Full Text] [Related]
60. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer.
Lee JW; Soung YH; Kim SY; Park WS; Nam SW; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2005 Jan; 113(3):510-1. PubMed ID: 15455340
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
